 I'm Kinsey Grant and I'm here with Michael Redman, the CEO of Oncolic. So Mr. Redman, can you tell me a little bit more about what Oncolic does? Oncolic is a biopharmaceutical company that is targeting women's cancers. Our current focus is in ovarian cancer, but we have the ability to work in all the gynecological cancers and breast cancer. So can you tell me a little bit more about what your most exciting research is right now and what you've got coming down the pipeline? Our lead product is called Prolanta. It is a blocker or an antagonist of human prolactin. Not only human prolactin plays a role in lactation, but like a lot of other hormones, later plays a role in cancer proliferation. So our drug has a unique mechanism of action called autophagocytosis or autophagy and we believe that this is the only cancer drug in clinical trials that works by this novel mechanism of action. In fact, the 2016 Nobel Prize winner in medicine was Yoshinori Osumi, who is considered to be the grandfather and the pioneer in the area of autophagy.